An international team of over 80 researchers has identified 14 proteins in blood that predict lung cancer more than five years before diagnosis, offering a potential breakthrough in prevention strategies. The study, published in Cell, analyzed 48,000 samples from the UK Biobank and validated findings across eight global datasets, including one from Taiwan focusing on nonsmokers.

The researchers discovered that canakinumab, an anti-inflammatory drug made by Novartis, nearly halved lung cancer risk among patients with elevated protein levels. While the drug showed only modest heart benefits in prior trials, this retrospective analysis revealed significant cancer prevention potential for a specific biomarker-defined population. However, the medication carries serious side effects including infection and sepsis risks.

This finding could reshape lung cancer screening protocols, which currently target smokers aged 50-80 with 20 pack-year histories. A blood test identifying high-risk individuals might improve screening efficiency and capture nonsmokers who fall outside current eligibility criteria. The approach mirrors how statins target high-cholesterol patients for heart attack prevention.

Clinical trials remain essential to prove whether canakinumab can safely prevent cancer at scale. Even if successful, the drug's toxicity may limit its use to carefully selected patients, potentially creating a niche market rather than broad application.